Lifespot Health Ltd
Appendix 4D
Half-year report

1. Company details

Name of entity:	Lifespot Health Ltd
ABN:	90 611 845 820
Reporting period:	For the half-year ended 30 June 2020
Previous period:	For the half-year ended 30 June 2019

2. Results for announcement to the market

				$
Revenues from ordinary activities	down	100%	to	Nil
Loss from ordinary activities after tax attributable to the owners of Lifespot Health Ltd	down	55.3%	to	(466,023)
Loss for the half-year attributable to the owners of Lifespot Health Ltd	down	55.3%	to	(466,023)

Dividends
There were no dividends paid, recommended or declared during the current financial period.

Comments
The loss for the consolidated entity after providing for income tax amounted to $466,023 (30 June 2019: $1,042,759).

3. Net tangible assets

	Reporting period Cents	Previous period Cents
Net tangible assets per ordinary security	0.50	0.44

4. Control gained over entities

Not applicable.

5. Loss of control over entities

Not applicable.

6. Dividends

Current period
There were no dividends paid, recommended or declared during the current financial period.

Previous period
There were no dividends paid, recommended or declared during the previous financial period.

7. Dividend reinvestment plans

Not applicable.

---

8. Details of associates and joint venture entities

Not applicable.

---

9. Foreign entities

Details of origin of accounting standards used in compiling the report:

Not applicable.

---

10. Audit qualification or review

Details of audit/review dispute or qualification (if any):

The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.

---

11. Attachments

Details of attachments (if any):

The Interim Report of Lifespot Health Ltd for the half-year ended 30 June 2020 is attached.

---

12. Signed

Signed Rodney Hannington

Date: 28 August 2020

Rodney Hannington
Chairman

Lifespot Health Ltd

ABN 90 611 845 820

Interim Report - 30 June 2020

Directors	Francesco Cannavo Rodney Hannington Justyn Stedwell
Company secretary	Justyn Stedwell
Registered office	Suite 103, Level 1 2 Queen Street, Melbourne VIC 3000 Ph : 03 8395 5446
Principal place of business	Suite 103, Level 1 2 Queen Street, Melbourne VIC 3000
Share register	Computershare Investor Services Pty Ltd 452 Johnston Street Abbbotsford Vic 3067 Ph : 03 9415 5000
Auditor	HLB Mann Judd (Vic Partnership) Level 9 575 Bourke Street Melbourne Vic 3000
Stock exchange listing	Lifespot Health Ltd shares are listed on the Australian Securities Exchange (ASX code: LSH)
Corporate Governance Statement	Refer to www.lifespot-health.com

The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of Lifespot Health Ltd (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 30 June 2020.

Directors

The following persons were directors of Lifespot Health Ltd during the whole of the financial half-year and up to the date of this report, unless otherwise stated:

Rodney Hannington - Executive Chairman
Francesco Cannavo - Executive Director
Justyn Stedwell - Non-Executive Director (appointed 19 May 2020)
Andreas Empl - Non-Executive Director (appointed 10 January 2020 and resigned 19 May 2020)
Greg Plunkett - Non-Executive Director (resigned 10 January 2020)

Principal activities

During the financial half-year the principal continuing activities of the consolidated entity consisted of:

- commercialising the BodyTel system; and
- developing and seeking to commercialise its smart cannabis vaporiser through its investment in Seng Vital Pty Ltd.

Review of operations

The loss for the consolidated entity after providing for income tax amounted to $466,023 (30 June 2019: $1,042,759).

During Q1 2020, the consolidated entity significantly reduced costs in the period from accelerated winding down of the operational management resources in Germany and redeploying some of these savings to transitioning of assets under Australian management. In addition, the Company invested in the extension of BodyTelTM knowhow and assets to the development of the FeverTelTM platform in response to the COVID-19 challenges facing the community and workplace.

The company relocated all BodyTelTM and Seng Vital digital, device and software assets to be under Australian control and has commenced the formal wind down process of the German operations.

With the recent acceleration of Telehealth systems driven by COVID-19 the Company continued to develop and roll-out Telehealth use cases for remote patient management and monitoring. In addition, the Company continues to advance projects that validate medical cannabis inhaler systems underpinned by digital health.

In June the company executed a Software License Agreement with Jayex Healthcare Limited (ASX: JHL), under which it has granted an exclusive license for the United Kingdom and a non-exclusive license for Australia. The Software License Agreement grants Jayex the rights to market and sell Lifespot Health's existing BodyTelTM software platform and integrated technology products and services along with all future telehealth products and services developed. The first use case is still under development.

In July the company launched the FeverTelTM Digital Thermometer (TGA listed Medical device Class IIa ARTG 338311) and APP for sale to households and small business's. The Company's FeverTelTM Digital Thermometer and APP allows families and small organisations of up to 10 people to track their body temperature and Flu / COVID symptoms via the FeverTelTM APP and Bluetooth connected dual mode digital thermometer. The Company has commenced selling FeverTelTM devices into large organisations. The Company has also advanced the development of a dedicated large enterprise "fit to work" platform via BodyTelTM.

During Q1 2020, following completion of tooling development the company provided Ionic Brands USA with the off-tooling prototype, however due to delays associated with COVID-19 the innovative smart vaporiser product is expected to be now launched in Ionic's key distribution states in the USA during Q4 2020.

Significant changes in the state of affairs

During the financial half-year the company issued 19,219,625 fully paid ordinary shares raising $634,248 before costs.

There were no other significant changes in the state of affairs of the consolidated entity during the financial half-year.

Matters subsequent to the end of the financial half-year
On 24 July 2020, the company issued 151,515 fully paid ordinary shares valued at $0.033 per share totalling $5,000, the funds in relation to these shares were received before 30 June 2020 and were recognised as a liability at 30 June 2020.

On 24 July 2020, the company issued 733,675 fully paid ordinary shares valued at $0.04 settling trade payable valued at $29,347.

The COVID-19 pandemic has created unprecedented economic uncertainty. Actual economic events and conditions in the future may be materially different from those estimated by the consolidated entity at the reporting date. As responses by government continue to evolve, management recognises that it is difficult to reliably estimate with any degree of certainty the potential impact of the pandemic after the reporting date on the consolidated entity's operations, its future results and financial position. The state of disaster in Victoria was declared on 16 August 2020 until 13 September 2020 and the state of disaster still in place. As stated in note 2, the consolidated entity's operation are of a scale and nature that they have not been significantly impacted and this still remains the case up to the date of signing.

No other matter or circumstance has arisen since 30 June 2020 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Impact of COVID 19 pandemic
During the current financial half-year the COVID 19 pandemic had a significant impact on the global economy.

The consolidated entity did not receive revenue from customers during the half-year ended 30 June 2020, meaning the impact of the pandemic has not been significant on the revenue front. For this reason the consolidated entity has not been entitled to any of the government financial stimulus measures. The consolidated entity's operations are of a scale that they have been able to be easily amended to adapt to various restrictions that have been imposed with minimal impact.

The statement of financial position at 30 June 2020 does not include material physical and intangible non-current assets that are required to be reviewed for impairment. For this reason the pandemic has not had an impact on the judgements and estimates that have been made in preparing these financial statements.

In March 2020, the company announced that it had extended its Bodytel platform to incorporate Bluetooth thermometers to support self and organisational fever monitoring. There is a large unmet demand for fever tracking as a result of the COVID 19 pandemic. During the financial half-year the consolidated entity spent $124,859 on product development, with further expenses incurred since 30 June 2020. On 24 June 2020, the Therapeutic Goods Administration listed the Fevertel dual mode (ear and forehead) infrared thermometer as a Class II medical device on the Australian Register of Therapeutic Goods.

In July 2020, the consolidated entity has recognised its first revenue in relation to the sale of its Fevertel thermometers.

Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.

This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.

On behalf of the directors

Rodney Hannington
Chairman

28 August 2020

Auditor's independence declaration

As lead auditor for the review of the interim financial report of Lifespot Health Ltd and the entities it controlled for the half-year ended 30 June 2020, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

(a) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and

(b) any applicable code of professional conduct in relation to the review.

This declaration is in respect of Lifespot Health Ltd and the entities it controlled during the period.

HLB Mann Judd
Chartered Accountants

Jude Lau
Partner

Melbourne
28 August 2020

Lifespot Health Ltd
Contents
30 June 2020

General information

The financial statements cover Lifespot Health Ltd as a consolidated entity consisting of Lifespot Health Ltd and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is Lifespot Health Ltd's functional and presentation currency.

Lifespot Health Ltd is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business is:

Suite 103, Level 1
2 Queen Street, Melbourne VIC 3000

A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.

The financial statements were authorised for issue, in accordance with a resolution of directors, on 28 August 2020.

Lifespot Health Ltd
Statement of profit or loss and other comprehensive income
For the half-year ended 30 June 2020

	Note	Consolidated Jun 2020 $	Jun 2019 $
Revenue and income		3,322	92,322
Interest revenue calculated using the effective interest method		125	17,185
Expenses			
Cost of sales		(104)	(81,270)
Consulting fees		(99,837)	(252,625)
Legal fees		(39,644)	(47,269)
Employee benefits expense		(27,937)	(195,828)
Audit fees		(16,742)	(9,754)
Depreciation and amortisation expense		-	(69,484)
Insurance		(30,364)	(29,812)
Directors' fees		(82,971)	(83,800)
Travel expenses		(836)	(155,722)
Impairment of receivables		-	(54,201)
Product development expenditure		(124,859)	-
Other expenses		(46,176)	(172,501)
Loss before income tax expense		(466,023)	(1,042,759)
Income tax expense		-	-
Loss after income tax expense for the half-year attributable to the owners of Lifespot Health Ltd		(466,023)	(1,042,759)
Other comprehensive income			
Items that may be reclassified subsequently to profit or loss			
Foreign currency translation		(2,853)	(5,235)
Other comprehensive income for the half-year, net of tax		(2,853)	(5,235)
Total comprehensive income for the half-year attributable to the owners of Lifespot Health Ltd		(468,876)	(1,047,994)
		Cents	**Cents**
Basic earnings per share from continuing operations	8	(0.55)	(1.34)
Diluted earnings per share from continuing operations	8	(0.55)	(1.34)

The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes

Lifespot Health Ltd
Statement of financial position
As at 30 June 2020

	Note	Consolidated Jun 2020 $	Consolidated Dec 2019 $
Assets			
Current assets			
Cash and cash equivalents		487,057	424,922
Trade and other receivables		113,848	95,333
Inventories		14,477	-
Other		41,199	31,859
Total current assets		656,581	552,114
Non-current assets			
Trade and other receivables		55,559	71,599
Intangibles		1,650	-
Total non-current assets		57,209	71,599
Total assets		713,790	623,713
Liabilities			
Current liabilities			
Trade and other payables		212,753	263,800
Contract liabilities		19,829	19,829
Total current liabilities		232,582	283,629
Total liabilities		232,582	283,629
Net assets		481,208	340,084
Equity			
Issued capital	4	8,853,191	8,243,190
Reserves		(968,064)	(965,211)
Accumulated losses		(7,403,919)	(6,937,895)
Total equity		481,208	340,084

The above statement of financial position should be read in conjunction with the accompanying notes

Lifespot Health Ltd
Statement of changes in equity
For the half-year ended 30 June 2020

Consolidated	Issued capital $	Reserves $	Accumulated losses $	Total equity $
Balance at 1 January 2019	8,243,190	(790,373)	(4,770,160)	2,682,657
Loss after income tax expense for the half-year	-	-	(1,042,759)	(1,042,759)
Other comprehensive income for the half-year, net of tax	-	(5,235)	-	(5,235)
Total comprehensive income for the half-year	-	(5,235)	(1,042,759)	(1,047,994)
Transactions with owners in their capacity as owners:				
Share-based payments	-	41,361	-	41,361
Balance at 30 June 2019	8,243,190	(754,247)	(5,812,919)	1,676,024

Consolidated	Issued capital $	Reserves $	Accumulated losses $	Total equity $
Balance at 1 January 2020	8,243,190	(965,211)	(6,937,896)	340,083
Loss after income tax expense for the half-year	-	-	(466,023)	(466,023)
Other comprehensive income for the half-year, net of tax	-	(2,853)	-	(2,853)
Total comprehensive income for the half-year	-	(2,853)	(466,023)	(468,876)
Transactions with owners in their capacity as owners:				
Contributions of equity, net of transaction costs (note 4)	610,001	-	-	610,001
Balance at 30 June 2020	8,853,191	(968,064)	(7,403,919)	481,208

The above statement of changes in equity should be read in conjunction with the accompanying notes

Lifespot Health Ltd
Statement of cash flows
For the half-year ended 30 June 2020

	Note	Consolidated Jun 2020 $	Jun 2019 $
Cash flows from operating activities			
Receipts from customers (inclusive of GST)		4,998	97,139
Payments to suppliers and employees (inclusive of GST)		(555,190)	(1,115,456)
		(550,192)	(1,018,317)
Interest received		125	21,696
Net cash used in operating activities		(550,067)	(996,621)
Cash flows from investing activities			
Payments for intangibles		(1,650)	-
Net cash used in investing activities		(1,650)	-
Cash flows from financing activities			
Proceeds from issue of shares	4	634,248	-
Share issue transaction costs		(24,247)	-
Net cash from financing activities		610,001	-
Net increase/(decrease) in cash and cash equivalents		58,284	(996,621)
Cash and cash equivalents at the beginning of the financial half-year		424,922	2,314,513
Effects of exchange rate changes on cash and cash equivalents		3,851	2,518
Cash and cash equivalents at the end of the financial half-year		487,057	1,320,410

The above statement of cash flows should be read in conjunction with the accompanying notes

Note 1. Significant accounting policies

These general purpose financial statements for the interim half-year reporting period ended 30 June 2020 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.

These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 31 December 2019 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.

The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated, throughout the body of the report.

New or amended Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period and there was no impact on applying these standards.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

Going concern
The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and settlement of liabilities in the ordinary course of business. The consolidated entity incurred a loss from ordinary activities of $466,023 for the half year ended 30 June 2020. In addition, the consolidated entity had negative cash from operating activities of $550,067.

The directors have reviewed the cashflow forecasts and believe that there are reasonable grounds to believe that the consolidated entity will be able to continue as a going concern due to the following factors:

- In July 2020, the consolidated entity has received its first revenue from its Fevertel thermometers;
- The directors are also exploring other opportunities to commercialise their existing technologies as well as other opportunities;
- The directors are of the opinion that the company will be able to access equity capital markets for any additional working capital requirements; and
- The consolidated entity has scaled back certain costs over the past six months. The loss for the current half year $456,166 compared to $1,042,759 in the six months ended 30 June 2019. The board retains the ability to further do this should it need to. The board has also committed to wind up the operations of its three German subsidiaries.

Accordingly, the directors believe that the consolidated entity will be able to continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the financial report. In the event that the consolidated entity is unsuccessful in implementing the above-stated initiatives, a material uncertainty exists, that may cast significant doubt on the consolidated entity's ability to continue as a going concern and its ability to recover assets and discharge liabilities in normal course of business and at the amounts shown in the financial report.

The financial report does not include any adjustments relating to the recoverability and classification of recorded asset amounts or to the amounts and classification of liabilities that might be necessarily incurred should the company not continue as a going concern.

Note 2. Impact of COVID 19 pandemic

During the current financial half-year the COVID 19 pandemic had a significant impact on the global economy.

The consolidated entity did not receive revenue from customers during the half-year ended 30 June 2020, meaning the impact of the pandemic has not been significant on the revenue front. For this reason the consolidated entity has not been entitled to any of the government financial stimulus measures. The consolidated entity's operations are of a scale that they have been able to be easily amended to adapt to various restrictions that have been imposed with minimal impact.

Note 2. Impact of COVID 19 pandemic (continued)

The statement of financial position at 30 June 2020 does not include material physical and intangible non-current assets that are required to be reviewed for impairment. For this reason the pandemic has not had an impact on the judgements and estimates that have been made in preparing these financial statements.

In March 2020, the company announced that it had extended its Bodytel platform to incorporate Bluetooth thermometers to support self and organisational fever monitoring. There is a large unmet demand for fever tracking as a result of the COVID 19 pandemic. During the financial half-year the consolidated entity spent $124,859 on product development, with further expenses incurred since 30 June 2020. On 24 June 2020, the Therapeutic Goods Administration listed the Fevertel dual mode (ear and forehead) infrared thermometer as a Class II medical device on the Australian Register of Therapeutic Goods.

In July 2020, the consolidated entity has recognised its first revenue in relation to the sale of its Fevertel thermometers.

Note 3. Operating segments

Identification of reportable operating segments
The consolidated entity is organised into one operating segments: being development of medical technologies. These operating segments are based on the internal reports that are reviewed and used by the Board of Directors (who are identified as the Chief Operating Decision Makers ('CODM')) in assessing performance and in determining the allocation of resources.

Note 4. Equity - issued capital

	Consolidated			
	Jun 2020 Shares	**Dec 2019 Shares**	**Jun 2020 $**	**Dec 2019 $**
Ordinary shares - fully paid	96,788,303	77,568,678	8,853,191	8,243,190

Movements in ordinary share capital

Details	**Date**	**Shares**	**Issue price**	**$**
Balance	1 January 2020	77,568,678		8,243,190
Issue of shares	2 March 2020	10,128,635	$0.033	334,245
Issue of shares	23 June 2020	9,090,990	$0.033	300,003
Less cost of capital raised		-	$0.000	(24,247)
Balance	30 June 2020	96,788,303		8,853,191

Ordinary shares
Ordinary shares entitle the holder to participate in dividends and the proceeds on the winding up of the company in proportion to the number of and amounts paid on the shares held. The fully paid ordinary shares have no par value and the company does not have a limited amount of authorised capital.

On a show of hands every member present at a meeting in person or by proxy shall have one vote and upon a poll each share shall have one vote.

Share buy-back
There is no current on-market share buy-back.

Note 5. Equity - dividends

There were no dividends paid, recommended or declared during the current or previous financial half-year.

Note 6. Contingent liabilities/assets

The consolidated entity has no contingent liabilities or assets.

Note 7. Events after the reporting period

On 24 July 2020, the company issued 151,515 fully paid ordinary shares valued at $0.033 per share totalling $5,000, the funds in relation to these shares were received before 30 June 2020 and were recognised as a liability at 30 June 2020.

On 24 July 2020, the company issued 733,675 fully paid ordinary shares valued at $0.04 settling trade payable valued at $29,347.

The COVID-19 pandemic has created unprecedented economic uncertainty. Actual economic events and conditions in the future may be materially different from those estimated by the consolidated entity at the reporting date. As responses by government continue to evolve, management recognises that it is difficult to reliably estimate with any degree of certainty the potential impact of the pandemic after the reporting date on the consolidated entity's operations, its future results and financial position. The state of disaster in Victoria was declared on 16 August 2020 until 13 September 2020 and the state of disaster still in place. As stated in note 2, the consolidated entity's operation are of a scale and nature that they have not been significantly impacted and this still remains the case up to the date of signing.

No other matter or circumstance has arisen since 30 June 2020 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.

Note 8. Earnings per share

	Consolidated	
	Jun 2020	**Jun 2019**
	$	**$**
Loss after income tax attributable to the owners of Lifespot Health Ltd	(466,023)	(1,042,759)
	Number	**Number**
Weighted average number of ordinary shares used in calculating basic earnings per share	84,596,552	77,568,678
Weighted average number of ordinary shares used in calculating diluted earnings per share	84,596,552	77,568,678
	Cents	**Cents**
Basic earnings per share from continuing operations	(0.55)	(1.34)
Diluted earnings per share from continuing operations	(0.55)	(1.34)

Lifespot Health Ltd
Directors' declaration
30 June 2020

In the directors' opinion:

- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 30 June 2020 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable, based on the factors outlined in Note 1 of the financial statements Going Concern.

Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.

On behalf of the directors

Rodney Hannington
Chairman

28 August 2020

Independent Auditor's Review Report to the Members of Lifespot Health Ltd

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Lifespot Health Ltd ("the company") and its consolidated entities ("the Group"), which comprises the consolidated statement of financial position as at 30 June 2020, the statement of profit or loss and other comprehensive income, the statement of changes in equity and the statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory notes, and the directors' declaration, for the consolidated entity comprising the company and the entities it controlled at the half-year end or from time to time during the half-year.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of the Group is not in accordance with the *Corporations Act 2001* including:

(a) giving a true and fair view of the Group's financial position as at 30 June 2020 and of its performance for the half-year ended on that date; and
(b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Material Uncertainty Regarding Going Concern

We draw attention to Note 1 Going Concern, in the half-year financial report, which indicates that the Group incurred a net loss after tax of $466,023 during the period ended 30 June 2020 (2019: loss of $1,042,759). As stated in Note 1, these events or conditions, indicate that a material uncertainty exists that may cast significant doubt on the Group's ability to continue as a going concern. Our conclusion is not modified in respect of this matter.

Directors' Responsibility for the Half-Year Financial Report

The directors of the Group are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity* in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the Group's financial position as at 30 June 2020 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of the Group, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

hlb.com.au

HLB Mann Judd (VIC Partnership) ABN 20 696 861 713
Level 9, 575 Bourke Street, Melbourne VIC 3000 | GPO Box 2850, Melbourne VIC 3001
T: +61 (0) 3 9606 3888 F: +61 (0) 3 9606 3800 E: mailbox@hlbvic.com.au

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*.

HLB Mann Judd	**Jude Lau**
Chartered Accountants	**Partner**

Melbourne
28 August 2020